drugset / Trial / NCT03303313
A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of Cemdisiran in patients with aHUS.
Timeline
- Start
- 2017-09-19
- Primary completion
- 2018-09-12
- Completion
- 2018-09-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemdisiran | Small interfering RNA (siRNA) | — | Subcutaneous |